What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
The impact of device education on patients with chronic obstructive pulmonary disease using different inhalers Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020
Improving inhaler use in COPD and the role of patient preference Source: Eur Respir Rev 2005; 14: 85-88 Year: 2005
Medical personnel‘s ability to use pressurized metered dose inhaler (pMDI) in India Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Analysis of peak inspiratory flow and use of dry powder inhalers in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients Source: Eur Respir J , 49 (2) 1601794; DOI: 10.1183/13993003.01794-2016 Year: 2017
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
A comparison of the accuracy of spirometers used for monitoring COPD Source: Annual Congress 2005 - Spirometry - now and in the future Year: 2005
How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Resistance to resistance Source: Annual Congress 2007 - Primary care: delivering the goods: "inhaled therapies" Year: 2007
Inhaler therapy in obstructive airways disease (OAD): prescription, compliance and technique Source: Eur Respir J 2006; 28: Suppl. 50, 57s Year: 2006
Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010
Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
Monitorization of β2-adrenergic effects in carriers of chronic obstructive pulmonary disease (COPD) using ultra-sonic and jet nebulization Source: Eur Respir J 2002; 20: Suppl. 38, 182s Year: 2002